Correction: Omole et al. Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age. Vaccines 2025, 13, 192

Q: What type of study is this?

This is a Human Clinical Trial study.

Tosin Omole; Enrique Pelayo; Aaron S. Weinberg; Spyros Chalkias; Zelalem Endale; Gretchen Tamms; Tina M. Sterling; Lori Good; Tulin Shekar; Morgan Johnson; Natalie Banniettis; Ulrike K. Buchwald; Alejandra Esteves-Jaramillo

doi:10.3390/vaccines13101056

October 16, 2025VaccinesOpen Access

Correction: Omole et al. Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age. Vaccines 2025, 13, 192

View Full Paper

Ask AI

Bookmark

Share

Key Points

The correction addresses key safety findings related to co-administration of vaccines in older adults, ensuring accurate data reporting.
Results indicate that the combination of pneumococcal vaccines and SARS-CoV-2 boosters presents acceptable tolerability profiles.
Immunogenicity of both pneumococcal vaccines is generally preserved when administered alongside the mRNA booster dose.
The implications of these findings suggest enhanced vaccination strategies for older adults to combat multiple viral infections.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Correction reports safety and immunogenicity of pneumococcal vaccines co-administered with mRNA-1273 in healthy adults, highlighting important implications for vaccination strategies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Omole et al. (2025) studied this question.

synapsesocial.com/papers/68f408995de60f8893c6fd06 https://doi.org/10.3390/vaccines13101056

View Full Paper

Ask AI

Bookmark

Share

Correction: Omole et al. Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age. Vaccines 2025, 13, 192

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Correction: Omole et al. Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age. Vaccines 2025, 13, 192

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

More related papers

More from Vaccines

Keep reading

More related papers

More from Vaccines